GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland Sells 1,078 Shares of Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 1,078 shares of GeneDx stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $89.44, for a total value of $96,416.32. Following the sale, the chief executive officer now directly owns 6,674 shares of the company’s stock, valued at $596,922.56. This represents a 13.91 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Katherine Stueland also recently made the following trade(s):

• On Monday, March 17th, Katherine Stueland sold 10,559 shares of GeneDx stock. The stock was sold at an average price of $96.71, for a total transaction of $1,021,160.89.
• On Monday, March 10th, Katherine Stueland sold 2,731 shares of GeneDx stock. The stock was sold at an average price of $94.73, for a total transaction of $258,707.63.
• On Wednesday, January 29th, Katherine Stueland sold 1,657 shares of GeneDx stock. The shares were sold at an average price of $78.48, for a total transaction of $130,041.36.
• On Tuesday, January 7th, Katherine Stueland sold 51,420 shares of GeneDx stock. The stock was sold at an average price of $94.48, for a total value of $4,858,161.60.
• On Thursday, January 2nd, Katherine Stueland sold 18,006 shares of GeneDx stock. The shares were sold at an average price of $78.18, for a total value of $1,407,709.08.

GeneDx Stock Performance

NASDAQ:WGS opened at $94.46 on Tuesday. GeneDx Holdings Corp. has a twelve month low of $7.72 and a twelve month high of $115.60. The company has a quick ratio of 2.27, a current ratio of 2.40 and a debt-to-equity ratio of 0.25. The stock’s 50-day simple moving average is $84.69 and its 200 day simple moving average is $70.37. The firm has a market capitalization of $2.65 billion, a PE ratio of -48.19 and a beta of 1.91.

GeneDx (NASDAQ:WGS) last announced its quarterly earnings results on Tuesday, February 18th. The company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.66. The company had revenue of $95.64 million for the quarter, compared to analyst estimates of $82.24 million. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. On average, analysts anticipate that GeneDx Holdings Corp. will post 0.97 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently commented on WGS shares. The Goldman Sachs Group boosted their price target on GeneDx from $70.00 to $80.00 and gave the company a “neutral” rating in a research note on Wednesday, February 19th. TD Cowen boosted their target price on shares of GeneDx from $75.00 to $118.00 and gave the company a “buy” rating in a research report on Tuesday, January 7th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $72.33.

Institutional Trading of GeneDx

Hedge funds and other institutional investors have recently modified their holdings of the stock. Principal Financial Group Inc. bought a new position in shares of GeneDx in the 3rd quarter valued at $604,000. GSA Capital Partners LLP bought a new position in GeneDx in the third quarter valued at about $322,000. Royce & Associates LP acquired a new stake in shares of GeneDx during the third quarter valued at about $1,201,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of GeneDx during the third quarter worth about $2,547,000. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of GeneDx by 304.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 147,034 shares of the company’s stock valued at $6,240,000 after buying an additional 110,666 shares during the period. Institutional investors own 61.72% of the company’s stock.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.